ZA200502365B - Use of topical metronidazole in the treatment of anoractal diseases - Google Patents
Use of topical metronidazole in the treatment of anoractal diseases Download PDFInfo
- Publication number
- ZA200502365B ZA200502365B ZA200502365A ZA200502365A ZA200502365B ZA 200502365 B ZA200502365 B ZA 200502365B ZA 200502365 A ZA200502365 A ZA 200502365A ZA 200502365 A ZA200502365 A ZA 200502365A ZA 200502365 B ZA200502365 B ZA 200502365B
- Authority
- ZA
- South Africa
- Prior art keywords
- metronidazole
- topical
- topical composition
- composition
- patients
- Prior art date
Links
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 title claims abstract description 65
- 229960000282 metronidazole Drugs 0.000 title claims abstract description 62
- 230000000699 topical effect Effects 0.000 title claims abstract description 41
- 201000010099 disease Diseases 0.000 title description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 35
- 239000002687 nonaqueous vehicle Substances 0.000 claims abstract description 4
- 239000003981 vehicle Substances 0.000 claims description 10
- 239000000730 antalgic agent Substances 0.000 claims description 6
- 235000019271 petrolatum Nutrition 0.000 claims description 6
- 150000002430 hydrocarbons Chemical class 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 3
- 239000003871 white petrolatum Substances 0.000 claims description 3
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 230000002757 inflammatory effect Effects 0.000 abstract description 2
- 230000005855 radiation Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 208000009043 Chemical Burns Diseases 0.000 abstract 1
- 206010069808 Electrical burn Diseases 0.000 abstract 1
- 206010053615 Thermal burn Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000037380 skin damage Effects 0.000 abstract 1
- 238000007910 systemic administration Methods 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 18
- 230000036407 pain Effects 0.000 description 16
- 210000001072 colon Anatomy 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 210000000664 rectum Anatomy 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 10
- 208000011231 Crohn disease Diseases 0.000 description 8
- 241000792859 Enema Species 0.000 description 8
- 208000009531 Fissure in Ano Diseases 0.000 description 8
- 239000007920 enema Substances 0.000 description 8
- 229940095399 enema Drugs 0.000 description 8
- 238000010879 hemorrhoidectomy Methods 0.000 description 8
- 206010002153 Anal fissure Diseases 0.000 description 7
- 208000016583 Anus disease Diseases 0.000 description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- 208000025865 Ulcer Diseases 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 206010060708 Induration Diseases 0.000 description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000003890 fistula Effects 0.000 description 5
- 230000002980 postoperative effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 206010016717 Fistula Diseases 0.000 description 4
- 206010017912 Gastroenteritis radiation Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 210000002255 anal canal Anatomy 0.000 description 4
- 229940035676 analgesics Drugs 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000003533 narcotic effect Effects 0.000 description 4
- 206010036784 proctocolitis Diseases 0.000 description 4
- 208000020624 radiation proctitis Diseases 0.000 description 4
- 238000007464 sphincterotomy Methods 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000004264 Petrolatum Substances 0.000 description 3
- 208000002389 Pouchitis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 208000014617 hemorrhoid Diseases 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 229940066842 petrolatum Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010048946 Anal abscess Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010035043 Pilonidal cyst Diseases 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 206010038063 Rectal haemorrhage Diseases 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- -1 VaselineTM Chemical compound 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002052 colonoscopy Methods 0.000 description 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
- 229940063190 flagyl Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 2
- 229960000240 hydrocodone Drugs 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 208000014999 perianal Crohn disease Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 206010002180 Anal ulcer Diseases 0.000 description 1
- 208000019751 Anorectal disease Diseases 0.000 description 1
- 206010002582 Anorectal ulcer Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 208000000528 Pilonidal Sinus Diseases 0.000 description 1
- 206010036772 Proctalgia Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 208000015815 Rectal disease Diseases 0.000 description 1
- 206010064993 Rectal fissure Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 206010053459 Secretion discharge Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000884 anti-protozoa Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940124977 antiviral medication Drugs 0.000 description 1
- 229940003587 aquaphor Drugs 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 150000001621 bismuth Chemical class 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940072645 coumadin Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- JBIWCJUYHHGXTC-AKNGSSGZSA-N doxycycline Chemical compound O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O JBIWCJUYHHGXTC-AKNGSSGZSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940067232 ethanol 0.3 ml/ml medicated liquid soap Drugs 0.000 description 1
- 238000009541 flexible sigmoidoscopy Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229940095358 konsyl Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004084 narcotic analgesic agent Substances 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229940127216 oral anticoagulant drug Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- MTZBBNMLMNBNJL-UHFFFAOYSA-N xipamide Chemical compound CC1=CC=CC(C)=C1NC(=O)C1=CC(S(N)(=O)=O)=C(Cl)C=C1O MTZBBNMLMNBNJL-UHFFFAOYSA-N 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40635102P | 2002-08-26 | 2002-08-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200502365B true ZA200502365B (en) | 2006-07-26 |
Family
ID=31946965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200502365A ZA200502365B (en) | 2002-08-26 | 2005-03-22 | Use of topical metronidazole in the treatment of anoractal diseases |
Country Status (29)
Country | Link |
---|---|
US (5) | US20060240123A1 (zh) |
EP (1) | EP1545516B1 (zh) |
KR (1) | KR100991054B1 (zh) |
CN (2) | CN1678309A (zh) |
AT (1) | ATE406890T1 (zh) |
AU (1) | AU2003260736B8 (zh) |
BR (1) | BR0313824A (zh) |
CA (1) | CA2496864C (zh) |
CR (1) | CR7768A (zh) |
CU (1) | CU23436B6 (zh) |
CY (1) | CY1108601T1 (zh) |
DE (1) | DE60323380D1 (zh) |
DK (1) | DK1545516T3 (zh) |
EA (1) | EA008150B1 (zh) |
ES (1) | ES2312847T3 (zh) |
HK (1) | HK1077758A1 (zh) |
HR (1) | HRP20050258A2 (zh) |
IL (1) | IL167069A (zh) |
IS (1) | IS7761A (zh) |
MA (1) | MA27520A1 (zh) |
MX (1) | MXPA05002033A (zh) |
NO (1) | NO333670B1 (zh) |
NZ (1) | NZ538998A (zh) |
PL (1) | PL375560A1 (zh) |
PT (1) | PT1545516E (zh) |
RS (1) | RS20050170A (zh) |
UA (1) | UA81638C2 (zh) |
WO (1) | WO2004017962A2 (zh) |
ZA (1) | ZA200502365B (zh) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
MXPA05004278A (es) | 2002-10-25 | 2005-10-05 | Foamix Ltd | Espuma cosmetica y farmaceutica. |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
JP2007529510A (ja) * | 2004-03-16 | 2007-10-25 | インターシア・コーポレイション | 細胞接着を抑制するメチマゾール誘導体及び互変異性環状チオン |
US20060211752A1 (en) | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
US7928132B2 (en) * | 2004-08-06 | 2011-04-19 | Ohio University | Methods for the amelioration of episodes of acute or chronic ulcerative colitis |
ITMI20041295A1 (it) | 2004-06-25 | 2004-09-25 | Cosmo Spa | Composizioni farmaceutiche antimicrobiche orali |
CN1291754C (zh) * | 2005-07-12 | 2006-12-27 | 李赴朝 | 局麻药增效延时剂 |
FR2899475A1 (fr) * | 2006-04-10 | 2007-10-12 | Galderma Res & Dev | Composition pharmaceutique pour le traitement de la rosacee |
CN100421648C (zh) * | 2006-08-15 | 2008-10-01 | 苏州市立医院 | 氢化考的松灌肠剂及其制备方法 |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
WO2009090558A2 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
AU2009244190B2 (en) * | 2008-05-07 | 2016-02-25 | Salix Pharmaceuticals, Ltd. | Methods of treating bowel disease by administering a bowel cleanser and an antibiotic |
WO2010125470A2 (en) | 2009-04-28 | 2010-11-04 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
CA2769677A1 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
CA2769625C (en) | 2009-07-29 | 2017-04-11 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
CA2776471C (en) | 2009-10-02 | 2019-02-12 | Foamix Ltd. | Surfactant-free, water-free, foamable compositions and breakable foams and their uses |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
IT1396731B1 (it) * | 2009-11-25 | 2012-12-14 | Masci | Composizione farmaceutica a base di metronidazolo ed ossido di zinco per il trattamento topico di patologie anali acute e croniche distrofiche e post-operatorie |
US20120177582A1 (en) * | 2011-01-11 | 2012-07-12 | Ramirez Jose E | Compositions for anorectal use and methods for treating anorectal disorders |
US8952057B2 (en) * | 2011-01-11 | 2015-02-10 | Jr Chem, Llc | Compositions for anorectal use and methods for treating anorectal disorders |
WO2013012662A2 (en) * | 2011-07-15 | 2013-01-24 | S.L.A. Pharma Ag | Pharmaceutical compositions for rectal administration |
CN102920665B (zh) * | 2012-12-04 | 2014-06-11 | 四川省川龙动科药业有限公司 | 结肠靶向氧化锌微丸及其制备方法 |
US9750723B2 (en) | 2013-10-31 | 2017-09-05 | Ohio University | Prevention and treatment of non-alcoholic fatty liver disease |
CN106659746A (zh) * | 2014-04-10 | 2017-05-10 | 国立研究开发法人理化学研究所 | 用于诱导th17细胞的组合物及方法 |
RU2605615C2 (ru) * | 2014-07-15 | 2016-12-27 | Общество с ограниченной ответственностью "Гелизовит" | Ректальный поликомплексный гель для лечения язвенного колита, болезни крона, свищей и осложнений, вызванных этими заболеваниями |
WO2016010610A2 (en) | 2014-07-18 | 2016-01-21 | Ohio University | Imidazole and thiazole compositions for modifying biological signaling |
US10588864B2 (en) | 2016-03-11 | 2020-03-17 | Gateway Pharmaceuticals LLC | Pharmaceutical compositions for colon-specific delivery |
CA2978573A1 (en) | 2016-09-08 | 2018-03-08 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US20190175558A1 (en) * | 2017-12-07 | 2019-06-13 | S.L.A. Pharma Ag | Topical pharmaceutical compositions for treatment of tissue damage |
US20210322458A1 (en) * | 2020-04-20 | 2021-10-21 | Gregg Tobin | Methods and compositions for treatment of burns, joint pain, and fungal infections |
WO2022123305A1 (en) * | 2020-12-07 | 2022-06-16 | S.L.A. Pharma Ag | Compositions comprising metronidazole for treatment of diabetic foot ulcers and venous ulcers |
US11951082B2 (en) | 2022-08-22 | 2024-04-09 | Ford Therapeutics, Llc | Composition of chlorhexidine |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3620674A1 (de) * | 1986-06-20 | 1987-12-23 | Nattermann A & Cie | Salbe zur behandlung von hauterkrankungen |
US4957918A (en) * | 1988-06-09 | 1990-09-18 | Leonard Bloom | Topical treatment of blepharitis |
CA2011423A1 (en) * | 1989-03-07 | 1990-09-07 | Peter M. Taylor | Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings |
US5143934A (en) | 1990-11-21 | 1992-09-01 | A/S Dumex (Dumex Ltd.) | Method and composition for controlled delivery of biologically active agents |
IN171919B (zh) * | 1989-11-01 | 1993-02-06 | Mcneil Ppc Inc | |
RU2128040C1 (ru) | 1996-03-19 | 1999-03-27 | Николай Васильевич Дмитриенко | Линимент "фузол" лекарственного препарата, обладающего противовоспалительным, ранозаживляющим и регенеративным действием, и способ его получения |
CN1202358A (zh) * | 1997-06-12 | 1998-12-23 | 马秀珍 | 治疗痤疮毛囊炎湿疹的水剂、膏剂 |
US5948400A (en) * | 1997-11-20 | 1999-09-07 | Smith & Nephew Inc. | Method of applying a pressure-sensitive adhesive wound dressing and water-based skin treatment composition |
AU773881B2 (en) * | 1999-07-16 | 2004-06-10 | Shoei Co., Ltd. | Nitroimidazole external preparations for dermatosis |
CN1291484A (zh) | 2000-08-18 | 2001-04-18 | 周文山 | 一种治疗前列腺的药物 |
UA53946A (uk) | 2002-03-25 | 2003-02-17 | Донецький Державний Медичний Університет Ім. М. Горького | Склад для лікування генералізованого пародонтиту у віл-інфікованих |
UA53946U (ru) | 2010-04-12 | 2010-10-25 | Тернопольский Национальный Технический Университет Имени Ивана Пулюя | Способ получения модифицированного эпоксикомпозитного покрытия |
-
2003
- 2003-08-22 US US10/525,208 patent/US20060240123A1/en not_active Abandoned
- 2003-08-22 KR KR1020057003310A patent/KR100991054B1/ko not_active IP Right Cessation
- 2003-08-22 BR BR0313824-0A patent/BR0313824A/pt not_active Application Discontinuation
- 2003-08-22 AU AU2003260736A patent/AU2003260736B8/en not_active Expired
- 2003-08-22 PL PL03375560A patent/PL375560A1/xx not_active Application Discontinuation
- 2003-08-22 CA CA002496864A patent/CA2496864C/en not_active Expired - Lifetime
- 2003-08-22 ES ES03792521T patent/ES2312847T3/es not_active Expired - Lifetime
- 2003-08-22 AT AT03792521T patent/ATE406890T1/de active
- 2003-08-22 UA UAA200502616A patent/UA81638C2/ru unknown
- 2003-08-22 EP EP03792521A patent/EP1545516B1/en not_active Expired - Lifetime
- 2003-08-22 DE DE60323380T patent/DE60323380D1/de not_active Expired - Lifetime
- 2003-08-22 EA EA200500401A patent/EA008150B1/ru unknown
- 2003-08-22 DK DK03792521T patent/DK1545516T3/da active
- 2003-08-22 CN CNA038201747A patent/CN1678309A/zh active Pending
- 2003-08-22 WO PCT/GB2003/003692 patent/WO2004017962A2/en active IP Right Grant
- 2003-08-22 NZ NZ538998A patent/NZ538998A/en not_active IP Right Cessation
- 2003-08-22 MX MXPA05002033A patent/MXPA05002033A/es active IP Right Grant
- 2003-08-22 PT PT03792521T patent/PT1545516E/pt unknown
- 2003-08-22 RS YUP-2005/0170A patent/RS20050170A/sr unknown
- 2003-08-22 CN CN2010101145599A patent/CN101843614B/zh not_active Expired - Fee Related
-
2005
- 2005-02-23 IL IL167069A patent/IL167069A/en active IP Right Grant
- 2005-02-24 CU CU20050039A patent/CU23436B6/es not_active IP Right Cessation
- 2005-03-18 HR HR20050258A patent/HRP20050258A2/hr not_active Application Discontinuation
- 2005-03-21 MA MA28167A patent/MA27520A1/fr unknown
- 2005-03-21 IS IS7761A patent/IS7761A/is unknown
- 2005-03-22 ZA ZA200502365A patent/ZA200502365B/en unknown
- 2005-03-23 NO NO20051542A patent/NO333670B1/no not_active IP Right Cessation
- 2005-03-28 CR CR7768A patent/CR7768A/es not_active Application Discontinuation
- 2005-12-16 HK HK05111623A patent/HK1077758A1/xx not_active IP Right Cessation
-
2008
- 2008-11-26 CY CY20081101369T patent/CY1108601T1/el unknown
-
2010
- 2010-07-12 US US12/834,198 patent/US9655883B2/en active Active
-
2013
- 2013-03-15 US US13/834,281 patent/US10653671B2/en not_active Expired - Fee Related
-
2014
- 2014-05-28 US US14/288,686 patent/US10709689B2/en not_active Expired - Fee Related
-
2016
- 2016-08-11 US US15/234,084 patent/US10881640B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10709689B2 (en) | Pharmaceutical composition | |
Nicholson et al. | Topical metronidazole (10 percent) decreases posthemorrhoidectomy pain and improves healing | |
JP2728284B2 (ja) | 痔疾並びにその他の治療用組成物 | |
CA2446052A1 (en) | Compositions and methods for treating vulvovaginitis and vaginosis | |
EP2731605A2 (en) | Pharmaceutical compositions for rectal administration | |
WO1988005298A1 (en) | Use of anorectal compositions | |
US20190175558A1 (en) | Topical pharmaceutical compositions for treatment of tissue damage | |
US7060729B2 (en) | Composition and method for treating skin | |
JP4744143B6 (ja) | メトロニダゾールの使用方法 | |
JP2006501235A6 (ja) | 医薬組成物 | |
AU2023254258A1 (en) | Compositions and methods for the treatment of bacterial vaginosis | |
WO2023201341A2 (en) | Compositions and methods for the treatment of bacterial vaginosis | |
Pousa et al. | Burn unit treatment of three Stevens-Johnson syndrome cases with cryopreserved allograft | |
KR20040012779A (ko) | 외음부질염 및 질증을 치료하기 위한 항진균제를 포함하는조성물 | |
UA81063C2 (en) | Pharmaceutical compositions in the form of ointment for treatment of phimosis and balanoposthitis | |
UA16753U (en) | Phimostin, pharmaceutical composition in form of ointment for treating phimosis and balanopostitis | |
MX2007009121A (es) | Composicion farmaceutica que comprende la combinacion de un agente antimicrobiano y un agente inhibidor selectivo de la enzima encefalinasa, indicada para el control y tratamiento de la diarrea aguda de origen bacteriano. |